Conservative Treatment for Atlantoaxial Dislocation Patients Without Neurological Deficit

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorPeking University Third Hospital

About this trial

The goal of this observational study was to learn about the long-term clinical efficacy of conservative treatment in atlantoaxial dislocation patients without neurological deficit. The main question it aims to answer is:

Is surgical intervention always necessary in atlantoaxial dislocation patients without nerve deficit?

Patients who refuse surgical intervention will continue to be treated conservatively. Clinical outcomes will be summarized over five years of follow-up

Eligibility criteria

Qualifiers

The patients meet the diagnostic criteria for atlantoaxial dislocation, that is, the ADI exceeds the normal range: it is over 3 mm in adults and over 5 mm in children.

The patients have no clinical manifestations of the nervous system, including occipital neuralgia, manifestations of cranial nerve impairment (such as dysphagia, dysarthria, nystagmus, etc.) and manifestations of spinal cord impairment (such as unsteadiness in holding objects, unsteady gait, decreased limb muscle strength, etc.).

After fully understanding their own conditions as well as the advantages, disadvantages and risks of both conservative treatment and surgical treatment, the patients can choose the initial treatment method on their own. If they choose conservative treatment, they will be included in the conservative treatment. If they choose surgical treatment, they will be included in the surgical intervention group.

Disqualifiers

Patients who have undergone surgeries in the cranio-cervical junction previously.

Patients with infections or tumors in the cranio-cervical junction.

Patients with fresh fractures in the cranio-cervical junction.

Patients with clinical manifestations of nerve deficit.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

300 Participants
are grouped into 2 trial groups

Sponsors and collaborators

Peking University Third Hospital

Lead sponsor

The First Affiliated Hospital of Zhengzhou University

Collaborator

Shanxi Medical University Second Hospital

Collaborator

Sir Run Run Shaw Hospital

Collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Collaborator

Hebei Medical University Third Hospital

Collaborator

Shanxi Bethune Hospital

Collaborator

Daping Hospital of Army Medical University

Collaborator

Shengjing Hospital

Collaborator

Tianjin People's Hospital

Collaborator

First Affiliated Hospital of Kunming Medical University

Collaborator

Guilin Medical University, China

Collaborator